ClinicalTrials.gg
Status unknownNCT02000362Updated Sep 6, 2017

Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)

A Phase 1/2 interventional study of Stem cells in Crohn's Disease, sponsored by Kang Stem Biotech Co., Ltd.. Status unknown at 7 sites in Korea, Republic of. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-09-06.

Sponsored by Kang Stem Biotech Co., Ltd. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
19 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 117 studies in Crohn Disease with a site in Korea, Republic of — 31 open to participants now, 41 under way, 26 of them phase 3. Crohn Disease · Korea, Republic of.

Planned enrollment
86th of 95
24 · median 280
Started
2014
the only one that year
Phase 1/2
Only one
of the 117
Registered
28th of 117
by date

Among the 117 studies in Crohn Disease with a site in Korea, Republic of, this one is the 86th largest by planned enrollment of the 95 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 1/2, and was the 28th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

31 of the 117 studies in Crohn Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 19 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Crohn Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of phase I clinical trial is to evaluate safety and efficacy in subjects with moderately active Crohn's disease after injection for 28days.

The purpose of phase IIa clinical trial is to determine therapeutic safety and efficacy of FURESTEM-CD Inj. which is based on Crohn's disease activity index(CDAI)\<150 after injection.

Read the detailed description

Crohn's disease is mysterious chronic inflammatory bowel disease. It usually happen in the young age and last forever. It is not yet clearly known the origin of crohn's disease. However, crohn's disease therapy is getting developed by using immunosuppressant and TNF-alpha inhibitor. Nonetheless, some patients still don't react to TNF-alpha inhibitor which is most effective treatment. Also, Even though some other patients reacted to the treatment at first, the effect of treatment decreases over time. Plus, long-term use of TNF-alpha inhibitor can lead to complication of infection and occurrence of malignant tumor like lymphoma. Recently, treatment of intractable crohn's disease is attempted by using stem cell. Especially, Mesenchymal stem cell is well-known for immunosuppression, anti-inflammatory ability and cell differentiation ability to various lineage cell as non hematopoietic stromal cell.

When the body get infected by the pathogens, innate immune response operate as the primary defence mechanism. at this time, there are some receptors reacting first such as TLR(toll-like receptor) and NLR(nucleotide-binding oligomerization domain) which is located in the cytoplasm of a cell. It is reported that the activities of TLR which is expressed by Mesenchymal stem cells play an important roles about immunomodulatory ability of Mesenchymal stem cells. Furthermore, human Umbilical Cord Blood derived-Universal Stem Cells( hUCB-USCs) manifest TLR and NLR of Mesenchymal Stem cells at the same time. when those receptors become activation, it maximize ability of immunomodulatory. Therefore, hUCB-USCs can be utilized to cure intractable autoimmune disease like Crohn's disease. Further, It has huge possibility as cell therapy products for autoimmune disease.

03

Conditions studied

  • Crohn's Disease

Keywords

  • Crohn's Disease
  • Stem cell
  • Cell therapy
  • Auto-immune disease
  • furestem
  • CD
  • inflammatory bowel disease
  • MSCs
  • Mesenchymal Stem Cells
  • hUCB-MSC
  • UCB-MSC
  • Umbilical cord Blood
04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. of either gender, aged≥19 and ≤70 years
  2. subjects who is diagnosed with Crohn's disease after considering all the factors below.

    1. histological or pathological Diagnostic opinion
    2. colonoscopic Diagnostic opinion
    3. radiologic and hematological Diagnostic opinion
  3. subjects who is included in two criteria below and come under CDAI 220-450 during screening period.

    1. CRP>0.3mg/dL during screening period
    2. more than 3 nonanastomotic ulcers which is included in Crohn's disease as a result of colonoscopy on screening period(each diameter of ulcers needs to exceed 0.5cm)
  4. range of Crohn's disease : an affection of ileum, an affection of large intestine, an affection of ileum and large intestine at once.
  5. subjects who suffer from extensive colitis during more than 8 years or limited colitis during more than 12 years need to have evidence that there are no large intestine ulcers by surveillance colonoscopy on screening visit.
  6. subjects who are included in two criteria about drug treatment of Crohn's disease like below.

    1. subjects who fail the existing treatment and come under more than 1 criterion as below.

      • subjects who continuously administer or (AZA, Methotrexate, 6-MP)
      • subjects who have history of improper response or intolerance about Corticosteroid or immunosuppressant (AZA, Methotrexate, 6-MP)
      • subjects who are dependent Corticosteroid or have history of Corticosteroid dependence.
    2. subjects who have history of improper response or intolerance about anti-TNF treatment as below.

      • Infliximab
      • Adalimumab
      • Certolizumab pegol
  7. subjects who satisfy those clinical examination value below during screening period.

    • ≥ 8.0g/dL
    • WBC ≥ 3,000/μL
    • Lymphocyte ≥ 500/μL
    • 100,000/μL ≤ ≤ 1,200,000/μL
    • and ALT ≤ 3 x the
    • ALP ≤ 3 x the upper limit of normal
    • Serum creatinine ≤ the upper limit of normal
    • Serum albumin ≥ 2.0g/dL
    • PT ≤ the upper limit of normal
    • ≤ the upper limit of normal
  8. subjects who agree with those use of method during clinical trial period.

    1. woman : subjects who is applicable to more than 1 case below.

      • subjects who is for more than 1 years before screening visit.
      • surgically sterility.
      • If subjects are biological clock, subjects need to agree with prohibition on having sex with man or usage of more than 2 effective contraception from sign of form until end of the clinical study.
    2. man : even surgically sterility(for example, getting a vasectomy), in case of satisfy those conditions below.

      • subjects who agree with prohibition on having sex with woman or usage of effective barrier contraception from sign of informed consent form until end of the clinical study.
  9. subjects who understand and voluntarily sign an informed consent form.

Exclusion Criteria:

  1. Exclusion Criteria of gastrointestinal tract

    1. Crohn's disease which is invaded only proximal ileum.
    2. the evidence of an intra-abdominal abscess during screening period.
    3. the evidence of an abscess around the anus during screening period.
    4. conditions of subtotal colectomy or total colectomy.
    5. short bowel syndrome.
    6. subjects who conduct elemental diet, tube feeding or parenteral nutrition within 3 weeks before registration.
    7. subjects who have ileostomy or colostomy.
    8. subjects who remove existing seton before screening period.
    9. fixed bowel stricture which has symptoms.
    10. In case that the PI anticipate that subjects need to get a surgical intestinal tract surgery caused by Crohn's disease.
    11. non-removal of large intestine adenoma.
    12. chronic inflammation-associated dysplasia.
  2. Exclusion Criteria of drugs

    1. in case subjects administered more than one drug within 4 weeks before enrollment.

      • Cyclosporine, tacrolimus, thalidomide
      • Adalimumab
      • Intravenous adrenocortical steroid
    2. in case subjects administered more than one drug within 10 weeks before enrollment.

      • Infliximab
      • Cetolizumab pegol
      • All kinds of biologicals
    3. in case subjects administered 5-ASA or Corticosteroid local treatment(a suppository or enema) within 2 weeks before enrollment.
    4. in case concomitant drug use for CD treatment cannot observe stable dosage during clinical study period or specified period like below.

      • use of oral 5-ASA compound at least 4 weeks before enrollment
      • use of oral Corticosteroid (prednisolone ≤ 20mg/day or budesonide ≤9mg/day) at least 2 weeks before enrollment
      • use of antibiotics for CD treatment at least 2 weeks before enrollment. (ex. metronidazole)
      • use of immunosuppressant at least 4 weeks before enrollment.
  3. Exclusion Criteria of infectious disease

    1. acute or chronic hepatitis like below(typeA, typeB, typeC).

      • IgM anti-HAV positive
      • HBs-Ag, IgM , IgG anti-HBc positive. (It is possible to enroll the clinical study when a subject is anti-HBs Ab positive, given that the subject is both HBs-Ag and IgM anti-HBc negative or IgG anti-HBc positive.)
      • -Ab positive
    2. tuberculosis

      • status present active tuberculosis
      • latent tuberculosis : subjects who is applicable to more than 1 case below.

        • QuantiFERON TB-GOLD positive or 2times continuous indeterminate within 4weeks before registration.
        • more than 10mm in tuberculin skin test within 3 months before registration.(when subjects got injected prednisolone more than 15mg per day, limited tuberculin skin test value is 5mm)
        • In case of observation of pulmonary tuberculosis cicatrix through X-Ray within 3months before registration.
    3. All kinds of Congenital or Acquired Immunodeficiency Syndrome.
    4. all kinds of inoculation except influenza vaccine within 4weeks before registration.
    5. infection with in 4weeks before screening visit or during screening visit.(pneumonia, pyelonephritis, Infection of Clostridium difficile etc.)
  4. General exclusion Criteria a. subjects who experienced stem cell therapy. b. History of a malignant tumor except as noted below.

    • properly cured non- basal cell skin cancer
    • properly cured pinacocyte skin cancer which is not recurred at least 1 year before registration.
    • properly cured carcinoma in situ of uterine cervix which has not recurred at least 3 years before registration.

      c. malignant tumor which is not cured yet. d. subjects who are breast-feeding. e. unstable and not regulated disease(associated with cardiovascular, lung, liver, kidney, gastrointestinal tract, urogenital organs, hematologic, immune, endocrine/metabolism, etc.) which has possibility to hamper safety of subjects or cause confusion in clinical study.

      f. subjects who got general anesthesia surgery within 4weeks before registration or subjects who anticipated necessity of general anesthesia surgery during clinical study.

      g. major neurological history including stroke, multiple sclerosis, encephaloma, neurological degenerative disease.

      h. history of hypersensitive reaction about MR contrast medium. I. history of addictive drugs or alcohol with 1 years. j. active psychiatric problem which can hamper participation of clinical study. k. all kinds of problems which has possibility to hamper participation of study visit and observance of study procedure.

      l. Any other condition which the PI judges would make subject unsuitable for study participation.

      m. subjects who got injected other product within 4 weeks or at present.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Treatment

    cohort 1. 5.0 x 10\^7 stem cells after registration cohort 2. 1.0 x 10\^8 stem cells after registration

    Biological: Stem cells

Interventions

  • BiologicalStem cells

    Also known as: FURESTEM-CD Inj.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events, Ratio of patients who is applicable to CDAI<150

    on phase 1, Phase 2a

    Time frame: 4 weeks follow-up after treatment, 12 weeks follow-up after treatment

Secondary outcomes

  1. the ratio of patients who reduce CDAI over 70 as contrasted with baseline value

    on phase 2a

    Time frame: 12 weeks follow-up after treatment

  2. a variation of CRP value as contrasted with baseline

    on phase 2a

    Time frame: 12 weeks follow-up after treatment

  3. a variation of MR enterographic score as contrasted with baseline

    on phase 2a

    Time frame: 12 weeks follow-up after treatment

  4. a variation of fecal calprotectin as contrasted with baseline

    on phase 2a

    Time frame: 12 weeks follow-up after treatment

  5. a variation of IBDQ score as contrasted with baseline

    on phase 2a

    Time frame: 12 weeks follow-up after treatment

  6. a variation of SF-36 score as contrasted with baseline

    on phase 2a

    Time frame: 12 weeks follow-up after treatment

  7. reduction of the number of draining fistula

    on phase 2a

    Time frame: 12 weeks follow-up after treatment

  8. all kinds of adverse effects which occur during the clinical study

    on phase 2a

    Time frame: 12 weeks follow-up after treatment

07

Study locations

7 of 7 sites recruiting
  • Inje University Haeundae Paik Hospital
    Busan, 48108, Korea, Republic of
    Recruiting
    • Tae-oh Kim · Contact
  • Yeungnam University Medical Center
    Daegu, 42415, Korea, Republic of
    Recruiting
    • Byung-Ik Jang · Contact
  • Seoul National Universtiy Bundang Hospital
    Seongnam-si, 13620, Korea, Republic of
    Recruiting
    • Hyuk Yoon · Contact
    • Hyuk Yoon · Principal investigator
  • Severance Hospital
    Seoul, 03722, Korea, Republic of
    Recruiting
    • Jae-hee Cheon · Contact
  • Asan Medical Center
    Seoul, 138-736, Korea, Republic of
    Recruiting
    • Su-jung Kim · Contact
    • Ji-young Park · Contact
    • Suk-kyun Yang · Principal investigator
  • Soeul National University Hospital
    Soeul, 110-7441, Korea, Republic of
    Recruiting
    • Jong-pil Im · Contact
    • Jong-pil Im · Principal investigator
  • The Catholic University of Korea, St. Vincent'S Hospital.
    Suwon-si, 16247, Korea, Republic of
    Recruiting
    • Kang-moon Lee · Contact
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Sep 2018 and a completion of Oct 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2013
First posted
Dec 4, 2013
Start
Aug 2014
Primary completionEst.
Sep 2018
CompletionEst.
Oct 2018
Last update
Sep 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02000362
Lead sponsor
Kang Stem Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Dec 4, 2013
Start date
Aug 2014
Primary completion
Sep 2018 (estimated)
Completion
Oct 2018 (estimated)
Last update
Sep 6, 2017

Study contacts

Eun-ji Kang
Contact
ejkang@kangstem.com
Suk-kyun Yang
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem Cell

Start the discussion